[HTML][HTML] Low immunogenicity of tocilizumab in patients with rheumatoid arthritis
…, W Reiss, A Pethoe-Schramm, NL Mallalieu… - Annals of the …, 2017 - ard.bmj.com
Objective Subcutaneous (SC) and intravenous formulations of tocilizumab (TCZ) are
available for the treatment of patients with rheumatoid arthritis (RA), based on the efficacy and …
available for the treatment of patients with rheumatoid arthritis (RA), based on the efficacy and …
Safety and pharmacokinetic characterization of nacubactam, a novel β-lactamase inhibitor, alone and in combination with meropenem, in healthy volunteers
NL Mallalieu, E Winter, S Fettner, K Patel… - Antimicrobial agents …, 2020 - Am Soc Microbiol
Nacubactam is a novel β-lactamase inhibitor with dual mechanisms of action as an inhibitor
of serine β-lactamases (classes A and C and some class D) and an inhibitor of penicillin …
of serine β-lactamases (classes A and C and some class D) and an inhibitor of penicillin …
Subcutaneous dosing regimens of tocilizumab in children with systemic or polyarticular juvenile idiopathic arthritis
…, K Bharucha, W Douglass, M Bao, NL Mallalieu… - …, 2021 - academic.oup.com
Objectives To determine sc tocilizumab (sc-TCZ) dosing regimens for systemic JIA (sJIA)
and polyarticular JIA (pJIA). Methods In two 52-week phase 1 b trials, sc-TCZ (162 mg/dose) …
and polyarticular JIA (pJIA). Methods In two 52-week phase 1 b trials, sc-TCZ (162 mg/dose) …
Evidence of bioequivalence and positive patient user handling of a tocilizumab autoinjector
…, C Wells, W Douglass, NL Mallalieu - Expert Opinion on …, 2019 - Taylor & Francis
Background: The anti–interleukin-6 receptor antibody tocilizumab is approved for subcutaneous
injection using a prefilled syringe (PFS). We report results from a bioequivalence study …
injection using a prefilled syringe (PFS). We report results from a bioequivalence study …
[HTML][HTML] Intravenous dosing of tocilizumab in patients younger than two years of age with systemic juvenile idiopathic arthritis: results from an open-label phase 1 …
NL Mallalieu, S Wimalasundera, JC Hsu… - Pediatric …, 2019 - Springer
Background The anti–interleukin-6 receptor-alpha antibody tocilizumab was approved for
intravenous (IV) injection in the treatment of patients with systemic juvenile idiopathic arthritis (…
intravenous (IV) injection in the treatment of patients with systemic juvenile idiopathic arthritis (…
A double-tracer technique to characterize absorption, distribution, metabolism and excretion (ADME) of [14C]-basimglurant and absolute bioavailability after oral administration and …
…, M Zell, C Funk, T Hartung, A Gloge, NL Mallalieu - Xenobiotica, 2017 - Taylor & Francis
The emerging technique of employing intravenous microdose administration of an isotope
tracer concomitantly with an [ 14 C]-labeled oral dose was used to characterize the disposition …
tracer concomitantly with an [ 14 C]-labeled oral dose was used to characterize the disposition …
Identification of RO4597014, a glucokinase activator studied in the clinic for the treatment of type 2 diabetes
…, NR Scott, J Grimsby, NL Mallalieu - ACS Medicinal …, 2013 - ACS Publications
To resolve the metabolite redox cycling associated with our earlier clinical compound 2, we
carried out lead optimization of lead molecule 1. Compound 4 showed improved lipophilic …
carried out lead optimization of lead molecule 1. Compound 4 showed improved lipophilic …
Pharmacokinetics and pharmacodynamics of setrobuvir, an orally administered hepatitis C virus non-nucleoside analogue inhibitor
NL Mallalieu, MH Rahimy, CA Crowley… - Clinical …, 2014 - Elsevier
… NL Mallalieu owns shares in Hoffmann-La Roche; CA Crowley was a former employee of
Anadys, but does not currently hold any financial interest in either Anadys or Roche; and PF …
Anadys, but does not currently hold any financial interest in either Anadys or Roche; and PF …
Low Potential of Basimglurant to Be Involved in Drug-Drug Interactions: Influence of Non–Michaelis-Menten P450 Kinetics on Fraction Metabolized
…, Y Cleary, N Parrott, G Greig, NL Mallalieu - … of Pharmacology and …, 2017 - ASPET
… Wrote or contributed to the writing of the manuscript: Fowler, Mallalieu … Guerini E, Schadt
S, Greig G, Haas R, Husser C, Zell M, Funk C, Hartung T, Gloge A and Mallalieu NL (2016) A …
S, Greig G, Haas R, Husser C, Zell M, Funk C, Hartung T, Gloge A and Mallalieu NL (2016) A …
Effect of impaired renal function on the pharmacokinetics of tomopenem (RO4908463/CS-023), a novel carbapenem
NL Mallalieu, S Lennon, M Liu… - Antimicrobial agents …, 2008 - Am Soc Microbiol
The objective of this study was to assess the impact of impaired renal function on the
pharmacokinetics of tomopenem (RO4908463/CS-023), a novel carbapenem antibiotic, and its …
pharmacokinetics of tomopenem (RO4908463/CS-023), a novel carbapenem antibiotic, and its …